Dbv Technologies SA (UK) ((GB:0QAJ)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dbv Technologies SA is conducting a Phase 3 clinical study titled ‘Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers).’ The study aims to evaluate the 6-month safety of the DBV712 250 mcg epicutaneous immunotherapy in young children with peanut allergies, a significant concern for this age group.
The intervention being tested is the DBV712 250 mcg patch, designed to provide epicutaneous immunotherapy to children with peanut allergies. The patch is intended to offer a safe and effective treatment option for managing peanut allergies in toddlers.
The study is interventional, with a randomized allocation and a parallel intervention model. It employs triple masking, involving participants, care providers, and investigators, to ensure unbiased results. The primary purpose of the study is treatment-focused.
The study began on June 24, 2025, with the primary completion and estimated overall completion dates yet to be announced. The last update was submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study update could positively influence Dbv Technologies’ stock performance by demonstrating progress in developing a novel treatment for peanut allergies. The outcome may also impact investor sentiment favorably, as successful results could lead to a competitive advantage in the allergy treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.